Recently, Concino Biofraquency has attracted attention for "inhaling" the vaccine.
Following Shanghai, Zhejiang, Jiangsu and Tianjin, on the evening of November 17, according to the official account of WeChat , Beijing has recently launched the appointment vaccination of the Kangseno recombinant novel coronavirus vaccine (adenovirus type 5 vector). People who need to strengthen immunization to can make an appointment at the designated vaccination site, receive the new coronavirus vaccine for free, and undergo Concino biofortification.
What is the inhaled vaccine for COVID-19?
According to CanSino Biologics, the recombinant novel coronavirus vaccine Kovesa Wuyou is used for inhalation. Based on intramuscular injection of Covesa, the drug delivery method is innovative, and the vaccine is atomized into tiny particles through a nebulizer, and then inhaled from the oral cavity (vibrating screen technology provided by Aerogen). By simulating the process of natural infection of COVID-19, triple immunity of mucosa, humoral fluid and cells is stimulated to provide better protection for the recipient.
clinical data previously published in The Lancet shows that the COVID-19 vaccine, an inhaled form of conseno, is safer and more immunogenic in allogeneic boosting immunity.
"A significant feature of the inhaled vaccine of COVID-19 is that the vaccine is atomized into tiny particles through a nebulizer, and then inhaled into the upper respiratory tract, bronchial and lungs through the mouth to produce immunity ." Zhu Tao, chief scientific officer of Concino Biotechnology, said.
Who can choose this vaccine to strengthen immunity?
Kanseno Bio's WeChat official account shows that people aged 18 years old and above who have completed basic immunization (2 doses of inactivated vaccine or intramuscular recombinant COVID-19 vaccine) for 6 months can choose to inhale the COVID-19 vaccine to strengthen immunity.
Since the announcement of jointly developing the first adenovirus vector COVID-19 vaccine with Academician Chen Wei of the Institute of Military Medicine in 2020, Consino has begun to enter the public eye.
From the establishment of the new coronavirus project in January 2020, to the first patent for the new coronavirus vaccine in August 2020, and then to the results of the world's first phase I clinical trial of the first inhaled new coronavirus vaccine in July 2021, Consino was the first to enter the track of the new coronavirus vaccine.
In the secondary market, the share price of Concino Biotechnology Hong Kong stock has soared from HK$57.60 per share at the beginning of 2020 to HK$444.2 per share in February 2021. During this period, Kocino Biosea also successfully landed on the technology innovation board with the help of the new crown pneumonia vaccine.
Since 2022, the domestic and international vaccine market environment for COVID-19 has undergone tremendous changes. Compared with 2021, the demand for vaccines for COVID-19 has dropped significantly. Although the epidemic is still recurring, the bonus of the vaccine in the new coronavirus is clearly dissipating.
Kanseno Bio's third quarter report shows that in the first three quarters of 2022, the company achieved revenue of 707 million yuan, a year-on-year decrease of 77.08%; the net loss attributable to shareholders of listed companies was 474 million yuan, and increased by 135.57% year-on-year. As for the reasons for the loss, Consino Biologics said that it was mainly due to the sharp decline in demand for COVID-19 vaccines compared with the same period last year, product price adjustments, and depreciation of inventory signs of impairment.
Now, with the concept of "the world's first inhaled vaccine", Concino Bio has once again gained the attention of capital market . Can this make the market change expectations for Concino Biologics?
From the perspective of the secondary market, the concept of inhaled COVID-19 vaccine has significantly boosted market sentiment.
According to wind data, since Shanghai announced the launch of the inhaled COVID-19 vaccine on October 25, the Hong Kong stock price of Kangzhinuo Biotechnology Hong Kong has risen by 134.43% in total; A-shares have also risen by 73.61%. As of the close of November 17, the Hong Kong stock price of CanSino Biologics was HK$114.4 per share, with a total market value of HK$43.786 billion; the A-share was RMB224.13 per share, with a total market value of RMB39.373 billion.
Huaxin Securities research report shows that CanSino Biologics currently has an annual production capacity of 100 million doses, which can ensure sufficient supply. Huaxin Securities predicts that in 2023, the inhaled COVID-19 vaccine will usher in a period of high volume.
CITIC Securities believes that with the "upgrade" of the new crown pneumonia vaccine and the launch of inhaled dosage forms, the domestic needle market still has great potential.
